The 30 references in paper С. Гиляревский Р., И. Кузьмина М., М. Голшмид В., Г. Захарова Ю. (2016) “«НЕПОТЕРЯННОЕ ВРЕМЯ» В ПРОФИЛАКТИКЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ СТАТИНОВ С ЦЕЛЬЮ ПЕРВИЧНОЙ ПРОФИЛАКТИКИ” / spz:neicon:aterotromboz:y:2016:i:2:p:108-116

1
Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation, 2014, 129(25 suppl 2): 1-45.
(check this in PDF content)
2
Perk J, De Backer G, Gohlke H et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J, 2012, 33: 1635-1701.
(check this in PDF content)
3
The Guidelines Battle on Starting Statins. New Engl J Med, 2014, 370: 1652-1658.
(check this in PDF content)
4
Redberg RF, Katz MH. Healthy men should not take statins. JAMA, 2012, 307: 1491-1492.
(check this in PDF content)
5
Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular Disease. JAMA, 2013, 310: 2451-2452.
(check this in PDF content)
6
Yeboah J, Sillau S, Delaney JC et al. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J,2015, 169: 387-395.
(check this in PDF content)
7
Ford I, Murray H, McCowan C, Packard CJ. Long Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation, 2016 Feb 10. [Epub ahead of print].
(check this in PDF content)
8
Sever PS, Chang CL, Gupta AK et al. The AngloScandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J, 2011, 32: 2525-2532.
(check this in PDF content)
9
Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008, 359: 2195-220.
(check this in PDF content)
10
Goff DC, Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol,2014, 63: 2935-2959.
(check this in PDF content)
11
National Institute for Health and Care Excellence (NICE). Clinical Guideline CG181: lipid modification — cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: http://www.nice.org.uk/Guidance/cg181. Accessed July 26, 2014.
(check this in PDF content)
12
JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart, 2014, 100: ii1-67.
(check this in PDF content)
13
Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation,2010, 121: 1768-1777.
(check this in PDF content)
14
Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol, 2009, 54: 1209-1227.
(check this in PDF content)
15
Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. J Am Coll Cardiol, 2015, 66: 2699-2709.
(check this in PDF content)
16
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet, 2013, 382: 1762-1765.
(check this in PDF content)
17
Ridker PM, Wilson PW. A trial-based approach to statin guidelines. JAMA, 2013, 310: 1123-1124.
(check this in PDF content)
18
Ridker PM, Rose L, Cook NR. A Proposal to incorporate trial data into a hybrid ACC/AHA al— gorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol, 2015, 65: 942-948.
(check this in PDF content)
19
Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med, 2014, 174: 15-22.
(check this in PDF content)
20
Nordestgaard BG, Palmer TM, Benn M et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med,2012, 9: e1001212.
(check this in PDF content)
21
Jњrgensen AB, Frikke-Schmidt R, Nordestgaard BG et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med, 2014, 371: 32-41.
(check this in PDF content)
22
Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. Eur Heart J, 2015, 36: 2446-2453.
(check this in PDF content)
23
Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333: 1301-1307.
(check this in PDF content)
24
Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lova— statin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279: 16151622.
(check this in PDF content)
25
Sever PS, Dahlo_f B, Poulter NR et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than— average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361: 11491158.
(check this in PDF content)
26
Nakamura H, Arakawa K, Itakura H, et al. for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006, 368: 1155-1163.
(check this in PDF content)
27
Ridker PM, Danielson E, Fonseca FA et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359: 2195-2207.
(check this in PDF content)
28
Colhoun HM, Betteridge DJ, Durrington PN et al. for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364: 685-696.
(check this in PDF content)
29
Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.
(check this in PDF content)
30
McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin, 2003, 19: 689-698.
(check this in PDF content)